Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EPS (Basic): 2019-2025

Historic EPS (Basic) for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$0.19.

  • Allogene Therapeutics' EPS (Basic) rose 40.62% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.98, marking a year-over-year increase of 37.18%. This contributed to the annual value of -$1.32 for FY2024, which is 36.84% up from last year.
  • Allogene Therapeutics' EPS (Basic) amounted to -$0.19 in Q3 2025, which was up 17.39% from -$0.23 recorded in Q2 2025.
  • Allogene Therapeutics' 5-year EPS (Basic) high stood at $0.01 for Q4 2021, and its period low was -$0.69 during Q1 2023.
  • Its 3-year average for EPS (Basic) is -$0.38, with a median of -$0.35 in 2024.
  • Per our database at Business Quant, Allogene Therapeutics' EPS (Basic) soared by 100.93% in 2021 and then slumped by 6,900.00% in 2022.
  • Allogene Therapeutics' EPS (Basic) (Quarterly) stood at $0.01 in 2021, then tumbled by 6,900.00% to -$0.68 in 2022, then climbed by 25.00% to -$0.51 in 2023, then surged by 45.10% to -$0.28 in 2024, then soared by 40.62% to -$0.19 in 2025.
  • Its last three reported values are -$0.19 in Q3 2025, -$0.23 for Q2 2025, and -$0.28 during Q1 2025.